BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li L, Nakano D, Zhang A, Kittikulsuth W, Morisawa N, Ohsaki H, Suzuki N, Yamamoto M, Nishiyama A. Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice. J Pharmacol Sci 2020;144:229-36. [PMID: 33070842 DOI: 10.1016/j.jphs.2020.09.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhang A, Nakano D, Morisawa N, Kitada K, Kittikulsuth W, Rahman A, Morikawa T, Konishi Y, Nishiyama A. Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotally nephrectomized rats. J Pharmacol Sci 2021;146:98-104. [PMID: 33941326 DOI: 10.1016/j.jphs.2021.03.007] [Reference Citation Analysis]
2 Kobayashi H, Davidoff O, Pujari-Palmer S, Drevin M, Haase VH. EPO synthesis induced by HIF-PHD inhibition is dependent on myofibroblast transdifferentiation and colocalizes with non-injured nephron segments in murine kidney fibrosis. Acta Physiol (Oxf) 2022;:e13826. [PMID: 35491502 DOI: 10.1111/apha.13826] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li A, Yuan JF, Gong Q, Zhang N, Chen LY, Luo YY, Cui YR, Wang HL, Liu RH. Effects of Eucommia ulmoides extract against renal injury caused by long-term high purine diets in rats. Food Funct 2021;12:5607-20. [PMID: 34018492 DOI: 10.1039/d0fo02802a] [Reference Citation Analysis]
4 Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T. Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial. Am J Nephrol 2021;52:871-83. [PMID: 34569489 DOI: 10.1159/000518071] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Xu X, Yu Z, Han B, Li S, Sun Y, Du Y, Wang Z, Gao D, Zhang Z. Luteolin alleviates inorganic mercury-induced kidney injury via activation of the AMPK/mTOR autophagy pathway. J Inorg Biochem 2021;224:111583. [PMID: 34428638 DOI: 10.1016/j.jinorgbio.2021.111583] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lee KH, Ho Y, Tarng DC. Iron Therapy in Chronic Kidney Disease: Days of Future Past. Int J Mol Sci 2021;22:1008. [PMID: 33498292 DOI: 10.3390/ijms22031008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Miao M, Wu M, Li Y, Zhang L, Jin Q, Fan J, Xu X, Gu R, Hao H, Zhang A, Jia Z. Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases. Front Pharmacol 2022;13:837249. [PMID: 35281917 DOI: 10.3389/fphar.2022.837249] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Noonan ML, Ni P, Agoro R, Sacks SA, Swallow EA, Wheeler JA, Clinkenbeard EL, Capitano ML, Prideaux M, Atkins GJ, Thompson WR, Allen MR, Broxmeyer HE, White KE. The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model. J Bone Miner Res 2021;36:1117-30. [PMID: 33592127 DOI: 10.1002/jbmr.4272] [Reference Citation Analysis]